Mastek is a mid-market IT services and digital engineering firm operating primarily across the United Kingdom, North America, and the AMEA region, focusing on healthcare, public sector, and financial services verticals. The company sits in the enterprise application transformation value chain, integrating platforms like Oracle and Salesforce while increasingly layering on AI-led modernization. Its competitive structure is that of a champion challenger, competing against larger Indian IT service integrators by offering aggressive pricing of 15% to 25% discounts on renewals and net new wins. Historically, the business has maintained blended EBITDA margins around 15.5% to 16.1%, which indicates average to good business quality for a mid-tier IT firm, but margins have been suppressed by mix shifts toward lower-margin Data and AI work and upfront discounts on large United Kingdom renewals.
The economics of this business persist primarily through high switching costs and deep domain qualification in niche verticals like the United Kingdom secured government services and NHS healthcare. The data shows the company securing long-term contracts, such as a GBP 50 million-plus AI-led engineering services deal and a 3-year data modernization contract for the Bank of England, which provide 3-year to 5-year visibility. However, the business is not immune to commoditization pressures. Management explicitly notes aggressive price competition in net new wins and renewals, with discounts reaching 20% to 25% in extreme cases. The moat is underpinned by mission-critical integration work and specialized Oracle Health cloud migration capabilities, but the persistent need to offer 15% to 30% productivity savings to clients to win outcome-based contracts shows that pricing power remains a structural challenge.
The inflection over the next 18 to 24 months hinges on the conversion of a strengthening order backlog into revenue, alongside a turnaround in North America. As of Q1 FY27, the 12-month order backlog stood at $310 million, growing 13.3% year-over-year in USD terms and 25% in INR terms. By H2 FY27, management expects the North America business to act as a growth engine, requiring a ramp-up to a $28 million to $30 million quarterly run-rate from its current stagnated $20 million to $23 million levels to deliver healthy mid-teens margins. Concurrently, the transition from time-and-materials to outcome-based contracts offering 15% to 30% client savings is expected to accelerate. If executed, the business 18 to 24 months out will feature revenue growth outpacing headcount growth, driving improved revenue per resource, while EBITDA margins stabilize around 16% for FY27, balancing AI-led operational efficiency against wage hikes and pricing pressures.
Management's walk-talk shows a mixed trajectory of delayed promises but improving order momentum. In October 2025, management guided for a positive H2 performance and expected North America margins to expand as the region approached a $28 million to $30 million run-rate. By January 2026, revenue declined 4.8% in constant currency due to furloughs and project right-shifting, pushing the North America inflection out to FY27. However, the UK healthcare business delivered over 24% dollar growth for FY26, and the 12-month order backlog consistently expanded from $280 million in October 2025 to $310 million by July 2026. Capital allocation remains conservative with no dilution; the company generated INR 542 crores of operating cash flow in FY26, ending Q1 FY27 with a net cash position that improved by INR 200 crore over two quarters, while actively pursuing smaller M&A for AI capabilities.
Earnings visibility is anchored by the $310 million 12-month order backlog and the expected H2 FY27 ramp-up of major deals like the FCA contract in the UK and a $25 million North America Salesforce transformation deal. For the earnings path to hold, the North America business must successfully scale to its targeted $28 million to $30 million quarterly run-rate, and the Middle East business must stabilize after geopolitical delays that impacted Q1 FY27 EBITDA by increasing bench costs and pushing DSO to 75 days. The single most important falsifier is the structural margin compression from outcome-based contracts. If the 15% to 30% productivity savings offered to clients fail to generate corresponding internal AI-led efficiency gains, revenue growth will lag headcount additions, and the targeted 16% EBITDA floor will break, confirming a structural shift to a lower-margin commodity game rather than a turnaround.
companyname: Mastek Limited ticker: MASTEK sector: IT Services / Digital Engineering & Cloud Transformation Mastek is an AI-first digital engineering and cloud transformation company incorporated in 1982, headquartered in Ahmedabad, with delivery centres across India, the UK, Europe, the Americas, and the Middle East. It helps enterprises modernise legacy systems, migrate to cloud platforms, and adopt AI across their operations. The company positions itself as a transformation partner for the p...
Read the full report →capex, order book surge
No guidance
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Mastek Limited and 4,900+ companies.
5-day free pass. No card required.